Introduction
receptors has allowed for investigations of the functional role of ET-1 in heart failure. Studies to date that have Endothelin-1 (ET-1) is a potent vasoconstrictor peptide assessed the effect of these antagonists have involved with diverse biologic actions [1] [2] [3] . The endothelin pepmostly the use of small animal models of heart failure tides interact with two receptor subtypes: the type A (ET ) [17] [18] [19] [20] [21] . The chronic effects of endothelin receptor an-A and type B (ET ) receptors [4] [5] [6] . The vasoconstrictive tagonists in large animal models of heart failure, which B effect of ET-1 is mediated mostly by the ET receptors more closely simulate human heart failure, have not been A [7] . Stimulation of the ET receptors by specific agonists assessed. Accordingly, the aim of the current study was to B elicits contraction as well as vasorelaxation, which is assess a potential pathogenetic role of ET-1 in chronic mediated by the release of nitric oxide and prostaglandins heart failure by examining the effects of chronic ET A [8] [9] [10] [11] . The plasma ET-1 level is elevated in animals receptor blockade on hemodynamics, left ventricular remodels of [12] [13] [14] and patients with heart failure [15, 16] .
modeling and neurohormonal parameters in a large animal The availability of specific antagonists of the endothelin model. To simulate clinical studies, we used a placebocontrol design and employed a canine model of car-diomyopathy that was induced by rapid pacing. This through the dorsal midscapular surface. The animals were pacing model closely mimics human cardiomyopathy and allowed to recover from the effects of general anesthesia has recently been recommended by a National Institute of for one week before the first baseline study measurements Health executive report to be one of the heart failure were taken. All hemodynamic studies were conducted models to be studied intensively [22] .
using local anesthetics and light morphine sedation (5-10 mg). Right sided hemodynamics were obtained from a thermodilution catheter and left ventricular as well as 2. Methods aortic pressures were obtained from a micromanometer-R tipped catheter (MIKRO-TIP , Millar Instruments, HousThe study group consisted of 17 male mongrel dogs ton, Texas, USA), which was introduced via the femoral with a mean weight of 22.161.4 kg (mean6SD). Nine vein and artery, respectively. After baseline clinical, dogs were randomized to receive placebo and eight dogs radiographic and echocardiographic assessments, as well were randomized to receive an orally active ET receptor as blood sampling for neurohormone measurements, the A antagonist. All paced dogs were preconditioned for at least pacemaker was programmed to initiate continuous right one week prior to the start of the study. There was free ventricular pacing at 250 beats / min. All dogs were paced access to water and dog chow. The investigation confor three weeks. 1 was infused into three Beagle dogs (weights 9 to 13.5 affinity (K 52 nM) and the affinity to human ET rei B kg), with and without pre-treatment with an oral ET ceptors is 184 nM [27] . In healthy volunteers, the agent A receptor antagonist. The dogs were anaesthetized with has been shown to have an oral bioavailability of 90%, intravenous pentobarbital sodium (30 mg / kg). Mean arwith rapid absorption (t of 1 to 2 h) and a half-life of 10 max terial pressure was measured via a catheter inserted into to 15 h [28] . In the course of preclinical development of the femoral artery and connected to a Statham P 23 DB the compound, the pharmacokinetic data were also meatransducer. Endothelin-1 (0.75 nmol / kg) was dissolved in sured in dogs and the values were very similar to those 0.5 ml / kg saline and injected into a leg vein over 2 min.
reported in human volunteers (M Kirchengast, personal Blood pressure was continuously recorded using a thercommunication). The oral regimen employed in this study moprinter (Gould 2000), from 10 min before ET-1 until 30 has been shown to significantly attenuate the pressor min after injection. Two days later, the ET receptor response to exogenous ET-1 [27] and this effect was A antagonist LU 135252 (50 mg / kg orally) was administered reproduced in our ET-1 challenge studies (see Section 3). to the same dogs and the exogenous ET-1 challenge
The rationale for administering LU 135252 on day three of studies were repeated 2 h after the administration of LU pacing was to initiate ET receptor blockade at a time A 135252. point equivalent to early heart failure in humans, since our previous studies on this model have demonstrated signifi-2.2. Induction of heart failure cant hemodynamic perturbation and cardiac chamber enlargement after one week of pacing [29, 30] . For both The method of induction of heart failure has been treatment groups, hemodynamic studies were repeated at a described previously [23] [24] [25] . In brief, under general common time point of two weeks of pacing, to assess the anesthesia, a unipolar pacing lead was advanced through impact of LU 135252 versus placebo treatment. Week two the external jugular vein into the right ventricular apex. A was chosen for the terminal hemodynamic study for the programmable pulse generator (Medtronic SX-5985, Medfollowing reasons. First, our experience had been that, by tronic Canada, Missisauga, ON, Canada) was inserted into week two, heart failure had already reached a moderately a subcuticular cervical pocket and a chronic cannula was severe stage and yet sudden death rarely occurred in these placed through the carotid artery, advanced to the aortic animals at this time. Second, we had demonstrated that by arch, tunneled underneath the skin and externalized the time of advanced heart failure, i.e. after four weeks or more of pacing, it was often difficult to detect a treatment compared by analysis of repeated measures variance with effect on hemodynamic parameters with agents such as the two factor design followed by post-hoc comparison using angiotensin converting enzyme inhibitor, enalapril, even Tukey's protected T-test (GB-STAT , Dynamic Mi-TM though severe heart failure did take a longer time period to crosystems Inc, Silver Spring, MD, USA). A probability develop and coronary endothelial function did improve in value of ,0.05 was considered to be statistically signifithe enalapril-treated group [31, 32] . LU 135252 was withcant. held on the morning of the week two hemodynamic study in order to avoid measuring the acute hemodynamic effects of the drug. The hemodynamic study was conducted 15 3. Results min after the resumption of sinus rhythm. Pacing and drug treatment were resumed after the hemodynamic study to 3.1. Endothelin-1 challenge study provide one further week of parallel assessment of echocardiographic and neurohormonal parameters of the two As shown in Fig. 1 , administration of ET-1 induced a study groups as severe heart failure evolved.
sustained increase in mean arterial pressure in the Beagle dogs. When ET-1 was readministered two days later, 2.4. Echocardiographic assessment of ventricular pretreatment with oral LU 135252 induced an initial remodeling decline in mean arterial pressure as well as completely inhibiting the ET-1-induced increase in blood pressure that Methods for the acquisition and analysis of sequential was observed two days earlier. echocardiographic data have been described in detail elsewhere [30, 33] . Data were acquired at baseline and 3.2. Development of heart failure weekly throughout the pacing period. Left ventricular volume and mass were calculated at end diastole using the After three weeks of continuous right ventricular pacing, formula for a hemispheric cylinder [30, 34, 35] . Left venboth the placebo-and LU 135252-treated mongrel dogs tricular mean wall thickness was derived by taking the developed severe heart failure, which was characterized by difference of the epicardial and endocardial short axis the development of lethargy, anorexia and ascites and diastolic cross-sectional areas [30, 35] . Left ventricular accompanied by radiographic evidence of cardiomegaly globularity was defined as the ratio of the chamber and pulmonary congestion. diastolic cross-sectional diameter (D) from the short axis view to the diastolic chamber length (L) from the long axis 3.3. Hemodynamic parameters view [30] . Left atrial volume was derived from the formula: (3 / 4)3(Area)3(Length), where Area was the The hemodynamic parameters of the placebo-and LU planimetered cross-sectional left atrial area obtained from 135252-treated dogs obtained at baseline and after two the short axis view at the level of the aortic valve and weeks of pacing, obtained during temporary cessation of Length was the longest anterior-posterior dimension of the pacing, are shown in Table 1 and the four panels of Fig. 2 . left atrium obtained from the apical four-chamber view There were no statistically significant differences between [36, 37] .
the two groups in any of the hemodynamic parameters at
Plasma neurohormonal parameters
The plasma atrial natriuretic peptide (ANP) level was determined on plasma extracted from C Sep-Pak col-18 umns (Waters, Milford, MA, USA) using a radioimmunoassay method. The plasma norepinephrine level was determined by a high-performance liquid chromatography method. Both assay methods have been reported in detail previously [37] .
Statistical analysis
Data are expressed as mean value6SD except in the figures where the data are expressed as mean value6SEM. The effects of LU 135252 or placebo on hemodynamic, echocardiographic and neurohormonal data within the baseline. In the placebo-treated dogs, the intrinsic heart slightly greater degree than in the placebo-treated dogs, but rate increased markedly after two weeks of pacing.
the difference was not significant. Systolic arterial pressure Systolic arterial pressure declined from 153626 mmHg at declined from 147619 mmHg at baseline to 120622 baseline to 126627 mmHg ( p,0.01) at two weeks. Mean mmHg ( p,0.001) at two weeks. Mean arterial pressure, arterial pressure, left ventricular dP/dt and 2dP/dt dedP/dt and 2dP/dt also declined to a similar extent as in clined significantly, whereas both systemic and pulmonary the placebo dogs. In contrast to the placebo dogs, the LU vascular resistance increased markedly. Right atrial pres-135252-treated dogs had no significant increase in either sure, pulmonary artery pressure and left ventricular end systemic or pulmonary vascular resistance. In the LU diastolic pressure all increased markedly, whereas cardiac 135252-treated dogs, there were significantly smaller inoutput declined. In the LU 135252-treated dogs, after two creases in right atrial pressure, mean pulmonary artery and weeks of pacing, the intrinsic heart rate increased to a left ventricular end diastolic pressure, and a smaller decline in cardiac output compared to the placebo dogs, reflecting the treatment effects of LU 135252 on these parameters. Finally, although LU 135252 had an effect on both systemic and pulmonary vascular resistance, the impact on pulmonary vascular resistance was greater than that on systemic vascular resistance.
Echocardiographic measures of cardiac remodeling
The echocardiographic parameters of both groups are shown in Table 2 . The data at baseline of the two groups are comparable. In both study groups, the left ventricular ejection fraction declined whereas the left ventricular end diastolic volume and left atrial volume both increased markedly. The diameter / length ratio (D/L) increased progressively, indicating increasing globularity, whereas left ventricular mass and derived mean wall thickness did not change significantly, suggesting the absence of significant hypertrophy at the whole-organ level. The changes in echocardiographic parameters over three weeks in both study groups were similar, indicating that LU 135252 had no significant impact on left ventricular diastolic chamber size, shape or mass.
Neurohormonal parameters
Changes in arterial plasma ANP and norepinephrine levels are shown in Fig. 3 . Baseline data were comparable in both groups. In both the placebo-and LU 135252-treated dogs, the plasma ANP level increased significantly after three days of pacing, increased further and plateaued gradually as severe heart failure developed over the three attenuated the increase in pulmonary artery and left involved the acute administration of the antagonists ventricular end diastolic pressure, the decline in cardiac [17, 18, 38, 39] . Only a limited number of studies have output and the increase in both systemic and pulmonary assessed the hemodynamic effects of long-term endothelin vascular resistance. Second, chronic ET receptor blockade receptor blockade in heart failure. All of these studies that A does not appear to have significant effects on left ventricuinvolved chronic ET receptor blockade have used small A lar chamber dimension, shape or mass, parameters that are animal models [19] [20] [21] . In rats with coronary artery commonly used in clinical trials to assess cardiac remodelligation [19] , infusion of the selective ET receptor pressure, the lack of an effect on left ventricular end completely abolished the pressor response to exogenous diastolic pressure in their study contrasts with our observa-ET-1. In addition, exogenous ET-1 in the presence of LU tions. It is possible that following myocardial infarction, 135252 produced a slight initial decline in arterial prescomplex processes, such as tissue inflammation, necrosis sure, suggesting an unmasking of ET receptor-mediated and collagen formation, are actively underway, and ET-1 B vasodilation. may play a pathogenetic role in one or more of these processes [40] , thereby confounding the interpretation of 4.2. Hemodynamic effects of chronic ET receptor the effects of endothelin receptor blockade. In a second A blockade study by the same investigators using the same model but with ET blockade initiated at ten days after the infarction, A Consistent with our previous reports in this model left ventricular end diastolic pressure was significantly [23, 24, 29] , chronic pacing resulted in a marked elevation reduced [20] . In a rabbit model of pacing-induced heart in pulmonary artery, right-and left-sided cardiac filling failure [21] , treatment with an ET receptor antagonist was A pressures, a significant decline in cardiac output and a initiated before the onset of pacing. The animals were marked increase in both systemic and pulmonary vascular studied after three weeks of pacing. The only in vivo resistance. LU 135252 ameliorated the elevation in pulhemodynamic parameters reported were mean arterial and monary artery and left ventricular end diastolic pressures. pulse pressures, which were both higher those of vehicleThis was accompanied by an improvement in cardiac treated rabbits. Cardiac output and cardiac filling pressures output. The marked increase in systemic and pulmonary were not measured. It is therefore difficult to compare this vascular resistance observed in the placebo dogs was study with ours in terms of in vivo hemodynamic parameattenuated in the LU 135252-treated dogs. Indeed, the ters. impact of LU 135252 on pulmonary vascular resistance appears to be more pronounced than that on systemic 4.
Effects of ET receptor blockade on left ventricular
A vascular resistance, an effect that is distinct from that of remodeling conventional afterload reducing agents. Given the almost comparable increase in intrinsic heart rate in the two Consistent with our previous reports [24, 25, 30] , pacing groups, the improvement in cardiac output produced by in the dog resulted in a markedly increased left ventricular volume and globularity, left atrial volume, and a marked hemodynamic status and, therefore, an improvement in decline in the left ventricular ejection fraction. Although baroreflex function [45] . Given the ongoing concern there was a trend towards increased mass and reduced regarding the relation of neurohormonal activation and mean wall thickness, these differences were not significant. increased mortality, raised by the results of clinical trials of Although one cannot rule out a type-II error for a modest vasodilator therapy in heart failure [46] , the lack of a increase in mass, cardiac hypertrophy at a whole-organ further increase in plasma norepinephrine levels associated level is likely to be modest, a finding also observed in with LU 135252 suggests that ET receptor blockade may A other pacing models [21] . The similar evolution of changes be better tolerated than other vasodilators in patients with in echocardiographic parameters in the placebo-and heart failure. actively treated animals suggests that, in this model, chronic ET receptor blockade has no significant impact A on left ventricular remodeling, at least using measures that 4.5. Study limitations are commonly employed in clinical trials. The lack of a significant improvement in ejection fraction and a reducSeveral aspects of our study warrant further discussion. tion in left ventricular diastolic volume was unexpected, First, the hemodynamic effects of ET blockade was not A given the marked improvement in cardiac output and the accompanied by any significant changes in cardiac reduction in filling pressures in the treated animals. The chamber dimensions. The heart failure induced in this reasons for these discrepant findings are unclear. However, the contractile performance of isolated myocytes mixed ET and ET receptor blockade using the same A B was completely restored in the treated rabbits, whereas model. myocyte dimensions were not altered to any great extent. One may therefore postulate that while ET receptor A blockade may improve isolated myocyte function, this benefit may not necessarily be manifested as a major 5. Conclusions improvement in the systolic performance at the wholeorgan level.
Using a large animal model of heart failure, which closely resembles human dilated cardiomyopathy, we have 4. 4 
. Effects of chronic ET receptor blockade on demonstrated that the administration of an ET receptor
A A neurohormonal activation antagonist is associated with favourable hemodynamic effects. Unlike some direct-acting vasodilators, these beneThe time course of the changes in plasma ANP and ficial hemodynamics effects are not accompanied by norepinephrine levels are consistent with our previous aggravation of neurohormonal activation. The results of reports [37, 41] . The lack of a significant lowering effect of our study support an important pathophysiologic role of chronic ET blockade on plasma ANP levels was un-ET-1 in chronic heart failure. Further studies that compare A expected, given the substantial lowering of cardiac filling chronic blockade of the receptor subtypes will provide pressures associated with ET blockade, as well as the more insights into the role of ET-1 as a potentially new A known stimulatory action of ET-1 on the secretion of ANP therapeutic modality in heart failure. [42] , an effect that is presumably mediated by an ET A receptor [43] . It is possible that the ET-1-induced ANP release is predominantly an in vitro phenomenon. The lack of a significant decrease in left atrial volume by ET
